Existing drugs used in the treatment of Parkinson's disease could be repositioned for use in the treatment of extreme drug-resistant tuberculosis, which kills about 2 million people each year, according to a new study. The rise of these strains of TB throughout the world, including industrialized countries, poses a great threat to human health.
-
ScienceDaily: Biotechnology News
-
Existing Parkinson's Disease Drug May Fight Drug-resistant TB
4 Jul 2009 | 8:00 am -
Methane-producing Molecule Can Also Repair DNA
3 Jul 2009 | 8:00 pmThe Archaea are single-celled organisms and a domain unto themselves, quite apart from the so called eukaryotes (bacteria and higher organisms). Many species live under extreme conditions, and carry out unique biochemical processes shared neither with bacteria nor with eukaryotes. Methanogenic archaeans, for example, can produce methane gas out of carbon dioxide and hydrogen. -
Computer Scientists Develop Model For Studying Arrangements Of Tissue Networks By Cell Division
3 Jul 2009 | 5:00 pmComputer scientists have developed a framework for studying the arrangement of tissue networks created by cell division across a diverse set of organisms, including fruit flies, tadpoles and plants. -
Why H1N1 Flu Spreads Inefficiently
3 Jul 2009 | 8:00 amScientists have found a genetic explanation for why the new H1N1 "swine flu" virus has spread from person to person less effectively than other flu viruses. But researchers say the new strain bears watching as it could mutate. -
Molecular Differences Found Between Embryonic Stem Cells And Reprogrammed Skin Cells
3 Jul 2009 | 5:00 amResearchers have found that embryonic stem cells and skin cells reprogrammed into embryonic-like cells have inherent molecular differences, demonstrating for the first time that the two cell types are clearly distinguishable from one another.
-
Smartbrief: Biotechnology Industry Organization
-
Want to read more from industry leaders?
1 Jul 2009 | 10:00 pmWant to read more from industry leaders? -More- -
Biofuel a boon to rural communities, Obama says
1 Jul 2009 | 10:00 pmBiofuel such as ethanol has benefited the economies of rural areas in the U.S. -More- -
Biogen acquires overseas rights to Acorda's MS drug
1 Jul 2009 | 10:00 pmBiogen Idec agreed to pay $110 million upfront to gain rights outside the U.S. -More- Hard Real-Time in a Standards-Based Platform for Manufacturing Exceed expectations for reliability, performance, and hard real-time while reducing production costs and time-to-solution by standardizing on one technology platform, from sensors to servers. Windows Embedded brings the ease and familiarity of Windows to the development and use of industrial devices and systems. Order free evaluation software. -
NanoCor gets $2.5M investment from Medtronic
1 Jul 2009 | 10:00 pmMedtronic has invested $2.5 million in NanoCor Therapeutics to help it develop and bring to market its gene therapy for conge -More- -
Stem cell discovery holds promise for damaged hearts
1 Jul 2009 | 10:00 pmStem cells called Isl1 that are found in developing hearts of human embryos can turn into any of the three major forms of car -More-
-
FierceBiotech
-
A fierce response from readers
2 Jul 2009 | 7:23 amWhen we ran the 2009 Fierce 15 report at the beginning of this week, we expected a big response. But even the optimists among the editorial crew here were surprised by the hard numbers. Monday provided the biggest single daily haul of page views in FierceBiotech's history. And Tuesday offered another bumper crop of readers. It all helped us make June the single biggest month ever for Web traffic. It's always a lot of fun to go out and select a list of developers doing exciting things in the world of biotechnology, and we appreciate your clear interest in the project. As I mentioned… -
Eisai creates jobs, readies Aricept NDA
2 Jul 2009 | 6:45 amJapan's Eisai has completed construction of a European Knowledge Centre in the UK, which could bring up to 250 jobs to the region. It's part of a £100 million effort to launch a strategic base giving Eisai it's first manufacturing facilities in Europe. In addition to the manufacturing capabilities, the project includes a research laboratory and offices. Eisai will move its R&D activities, drug production and marketing to the new headquarters, where 500 people are expected to be employed. Half of those will be newly-created positions. In a separate announcement, Eisai said that… -
King, Acura get FDA response letter
2 Jul 2009 | 6:10 amThe FDA has issued a Complete Response Letter to King Pharmaceuticals and Acura Pharmaceuticals regarding their NDA for the pain drug Acurox. The agency has questions about the potential abuse deterrent benefits of Acurox, which the two companies say they can address without having to conduct additional clinical trials. Report -
J&J to invest $1B in Elan, scoops up drug program
2 Jul 2009 | 5:22 amAfter months of rumors regarding potential deals, Ireland's Elan Pharmaceuticals announced this morning that Johnson & Johnson will invest a billion dollars into the company while taking control of Elan's rights in a key Alzheimer's drug program. J&J is taking over Elan's rights to the Alzheimer's program, which is partnered with Wyeth, through a newly formed company, initially committing $500 million into the development of the drug. And Elan will keep 49.9 percent of the new company, with a share of the profits and the royalties. "This transaction will leverage… -
Sanofi-Aventis wins big with Multaq approval
2 Jul 2009 | 5:05 amAfter a long, dry spell, Sanofi-Aventis' pipeline has finally produced a winner. The FDA has approved its blockbuster heart therapy Multaq. While expected, the news Thursday morning raised a swift cheer from the ranks of stock analysts. Sanofi has estimated Multaq's earnings potential at more than €1 billion a year. And some of the analysts' estimates go higher than that. "The drug is now approved, ending Sanofi's streak of pipeline futility," Gbola Amusa, an analyst with UBS, tells Dow Jones. Amusa believes that Multaq can earn €1.4 billion annually. While the road…
-
About.com Biotech / Biomedical
-
Riparian Buffers and Phytotechnology
1 Jul 2009 | 2:27 amI’ve been studying different types of phytoremediation lately and here’s a new form I’d never heard much about: The riparian buffer. Named after the riparian zone, A riparian buffer is... -
Phytoremediation Popularity Growing
29 Jun 2009 | 11:25 pmPhytoremediation is a form of bioremediation that makes use of plants to degrade or sequester contaminants in soil and groundwater. While the technology is not new, it seems current trends... -
Clues to Antibiotic Resistance in Superbugs
24 Jun 2009 | 3:30 amAntibiotic resistant bacteria, sometimes called "Superbugs" are becoming a widespread problem particularly in hospitals where immunocompromised patients can become very susceptible to infection. For example, we all have the bacterium... -
Scrawny Protease and Cell Differentiation
22 Jun 2009 | 3:30 amA new link between the protease activity of an enzyme called scrawny (scny), chromatin modification and cell differentiation, has been described in Science Magazine. Scientists from Howard Hugh Medical Institute... -
Evolution of Zinc Finger Protein Diversity
20 Jun 2009 | 3:30 amA large number of transcription factors in humans belong to a superfamily that shares a similar motif known as the zinc finger. Among these, a large proportion have multiple tandem...
-
Biotech Blog
-
Drug Patent Expirations in July 2009
1 Jul 2009 | 6:22 amCopyright © BiotechBlog.com, a product of thinkBiotech.com Courtesy of DrugPatentWatch.com: Drug Patent Expirations in July 2009 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration LEVULAN Dusa aminolevulinic acid hydrochloride 5,422,093 Jul 28, 2009 LEVULAN Dusa aminolevulinic acid hydrochloride 6,710,066 Jul 28, 2009 OPTIMARK Mallinckrodt gadoversetamide 5,130,120 Jul 14, 2009 OPTIMARK Mallinckrodt gadoversetamide 5,137,711 Jul 14, 2009 OPTIMARK IN PLASTIC CONTAINER Mallinckrodt gadoversetamide 5,130,120 Jul 14, 2009 OPTIMARK IN… -
Journal of Commercial Biotechnology — July 2009 issue now available
22 Jun 2009 | 12:20 pmCopyright © BiotechBlog.com, a product of thinkBiotech.com The July 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper: Volume 15, Issue 3 Editorial: The impact of the global financial crisis on biotechnology development (free full-text) Yali Friedman Can genetic engineering prevent food-poisoning? Henry Miller Maturation of the biotechnology industry changes job opportunities for scientists Helen Liu and Molly B. Schmid Biotechnology business models: An Indian perspective Viren Konde Tracking progress: Two… -
Innovating Across Borders
8 Jun 2009 | 10:44 amCopyright © BiotechBlog.com, a product of thinkBiotech.com Here is a recent keynote I gave for the Delaware Valley Innovation Network. The group is working on coordinating the activities of community colleges — and other parties – between the adjacent Delaware, Philadelphia, and New Jersey regions. My objective was to use case studies to show that drawing circles around regions to count combined assets (as is too frequently done) is not enough; it is also necessary to find ways to drive collaboration. The slideshow is shown below: Innovating Across Borders View more… -
Koronis: Developing a new treatment for HIV
3 Jun 2009 | 10:32 amCopyright © BiotechBlog.com, a product of thinkBiotech.com I recently had the opportunity to conduct a brief interview with Jeff Parkins, Vice President of Clinical Development and Regulatory at Koronis on his company and the future of the biotechnology industry: Can you tell me a little bit about Koronis and its mission? Koronis Pharmaceuticals develops anti-viral therapeutics based on Viral Decay Acceleration TM (VDA), a novel drug mechanism that accelerates the accumulation of genetic mutations in a viral genome and causes a degradation of viral fitness. Degrading fitness diminishes… -
Drug Patent Expirations in June 2009
1 Jun 2009 | 10:10 amCopyright © BiotechBlog.com, a product of thinkBiotech.com Courtesy of DrugPatentWatch.com: Drug Patent Expirations in June 2009 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration ADVIL COLD AND SINUS Wyeth Cons ibuprofen; pseudoephedrine hydrochloride 5,071,643 Jun 10, 2009 ADVIL COLD AND SINUS Wyeth Cons ibuprofen; pseudoephedrine hydrochloride 5,360,615 Jun 10, 2009 ALLI Glaxosmithkline Cons orlistat 4,598,089 Jun 18, 2009 Courtesy of DrugPatentWatch.com This information is also available in an email newsletter: Subscribe to the…
-
Terry Etherton Blog on Biotechnology
-
Risk Factors for Severe Swine Flu a Wide Umbrella Under which Many Stand
24 Jun 2009 | 5:59 amA ProMED-mail post (June 19, 2009) Whether speaking of a 58-year-old man or a 38-year-old woman, or a little boy of 9, officials announcing swine flu deaths are almost always quick to note “underlying health conditions” may have contributed to the fatal outcome. Asthma, heart disease, diabetes, maybe even obesity are among the conditions used to help explain why swine flu infection is hospitalizing and killing younger people, people who would be expected to make a full recovery from seasonal flu. It could create the impression that only the sickly are dying from the new H1N1 flu… -
The Slippery Slope Involved in the Proposed Move of the U.S. Foot and Mouth Disease Lab – What a “Mess”!
9 Jun 2009 | 12:48 pmBackground: Common to all fields of science and engaged scientists is their willingness to participate in the free exchange of ideas.This blog often posts such ideas in the form of existing citable scientific contributions and news items.In recent conversations among like-minded individuals regarding contemporary topics in livestock production agriculture and biotechnology, the issue of U.S. animal disease research was raised.No factor in livestock production can impact production efficiency and profitability more than a disease issue.And, in the case of a highly contagious foreign animal… -
INFLUENZA A (H1N1) – SWINE IMMUNITY
29 May 2009 | 11:38 amA ProMED-mail post (May 28, 2009) The following is [1] a statement of the research program of the United States Department of Agriculture (USDA) Agricultural Research Service (ARS), and [2] the outcome of a study of the cross-reactivity of serum samples from US pigs against the new swine origin 2009 H1N1 influenza virus (S/O H1N1). The results of this analysis indicate that pre-existing immunity induced by swine influenza viruses circulating in the US may not protect pigs against the new S/O H1N1 influenza virus presently circulating in people. Soon after the emergence of the H1N1 virus in… -
Devilish Dilemmas Surround Pandemic Flu Vaccine
27 May 2009 | 9:34 amMartin Enserink and Jocelyn Kaiser Published in SCIENCE: VOLUME 324:703-705,2009 If and when a pandemic of H1N1 swine flu hits, vaccines might be the world’s best hope for softening the blow. But major uncertainties cloud the prospects for vaccines against the new strain. No pandemic vaccine yet exists, and it is unclear how much vaccine would have to be available, and by what time, to have any impact. Should manufacturers halt the production of seasonal influenza vaccine to focus on a pandemic version, and if so, when? And is there any way to ensure that people around the world have an… -
Assessing the Severity of an Influenza Pandemic
13 May 2009 | 7:58 amFrom the World Health Organization Assessing the Severity of an Influenza Pandemic The major determinant of the severity of an influenza pandemic, as measured by the number of cases of severe illness and deaths it causes, is the inherent virulence of the virus. However, many other factors influence the overall severity of a pandemic’s impact. Even a pandemic virus that initially causes mild symptoms in otherwise healthy people can be disruptive, especially under the conditions of today’s highly mobile and closely interdependent societies. Moreover, the same virus that causes mild…
-
BIOTECH - Google News
-
Lost promise: Can region's shrinking biotech sector bounce back ... - Washington Business Journal
3 Jul 2009 | 7:18 pmLost promise: Can region's shrinking biotech sector bounce back Washington Business JournalBy 2000, their discoveries would end up mapping out the future of Montgomery County's biotech community. But nearly a decade later, a future that showed so and more » -
Johnson & Johnson buy $1.5 billion stake in Irish biotech Elan - Irish Central
3 Jul 2009 | 5:10 pmMedIndiaJohnson & Johnson buy $1.5 billion stake in Irish biotech ElanIrish CentralJohnson & Johnson has bought all of Elan's Assets in their Alzheimer's Immunotherapy Program for $1 billion and will receive 18.4 per cent of company shares Elan shares jump as J&J take 18pc stake in biotechHerald.ieJ&J to take $1bn stake in Ireland's ElanFinancial TimesJ&J Takes Up $1bn Elan StakeFinancier Worldwide - Corporate Finance IntelligenceThe Star-Ledger - NJ.com -New York Times -Wall Street Journalall 418 news articles » -
Official seeks to lure biotech to Brockton - Enterprise News
3 Jul 2009 | 4:12 pmOfficial seeks to lure biotech to BrocktonEnterprise NewsThe head of the Brockton 21st Century Corp. says the city must do more to attract biotechnology companies to locate here. and more » -
Big push underway for generic biotech drugs - San Jose Mercury News
3 Jul 2009 | 12:02 pmSDNN: San Diego News NetworkBig push underway for generic biotech drugsSan Jose Mercury NewsBiotech drugs were largely excluded from the 1984 landmark law that permitted the sale of generic medicines. Biotech: Is it time for generic biologics?SDNN: San Diego News NetworkAn Update Regarding Follow-On BiologicsLife Science Leader Magazineall 4 news articles » -
J&J says 84.4 pct of Cougar shares tendered - Reuters
3 Jul 2009 | 7:19 amJ&J says 84.4 pct of Cougar shares tenderedReuters[ID:nN21310649] On completion of the deal, Cougar will operate as a unit of Johnson & Johnson, and will work with Ortho Biotech Oncology Research Cougar Biotechnology Announces Successful Completion of Johnson istockAnalyst.com (press release)Johnson & Johnson Completes Initial Tender Offer for Cougar PR Newswire (press release)Johnson & Johnson Concludes Initial Tender Offer For Cougar RTT Newsall 29 news articles »
-
BIOTECHNOLOGY NEWS - Google News
-
Booming biotechnology industry works wonders for Wisconsin - Wausau Daily Herald
4 Jul 2009 | 2:30 amBooming biotechnology industry works wonders for WisconsinWausau Daily HeraldWisconsin's long history in biotechnology includes the development of vitamins B and D as well as the blood-thinner Warfarin, Still said. and more » -
Official seeks to lure biotech to Brockton - Enterprise News
3 Jul 2009 | 4:12 pmOfficial seeks to lure biotech to BrocktonEnterprise NewsThe head of the Brockton 21st Century Corp. says the city must do more to attract biotechnology companies to locate here. and more » -
AGRICULTURE: Biotechnology: Africa Must Not Be Left Behind - IPS
3 Jul 2009 | 2:31 pmAGRICULTURE: Biotechnology: Africa Must Not Be Left BehindIPSKAMPALA, Jul 3 (IPS) - Africa must embrace agricultural biotechnology or risk being excluded from a major technological revolution that has and more » -
Deals of the day -- mergers and acquisitions - Reuters
3 Jul 2009 | 2:02 pmDeals of the day -- mergers and acquisitionsReutersN) said about 84.4 percent of the outstanding shares of Cougar Biotechnology Inc (CGRB.O) were tendered during the initial offering period that ended and more » -
J&J says 84.4 pct of Cougar shares tendered - Reuters
3 Jul 2009 | 7:19 amJ&J says 84.4 pct of Cougar shares tenderedReutersN) said about 84.4 percent of the outstanding shares of Cougar Biotechnology Inc (CGRB.O) were tendered during the initial offering period that ended Cougar Biotechnology Announces Successful Completion of Johnson istockAnalyst.com (press release)Johnson & Johnson Completes Initial Tender Offer for Cougar PR Newswire (press release)Johnson & Johnson Concludes Initial Tender Offer For Cougar RTT Newsall 29 news articles »
-
CropBiotech Update
-
EU’s Top Scientific Body Reconfirms Safety of GM Maize
3 Jul 2009 | 2:00 amThe GMO Panel of the European Food Safety Authority (EFSA), EU's top food watchdog, has issued a new scientific opinion on the safety and renewal of authorization for continued marketing of the insect-resistant maize MON810, the only genetically modified crop approved for by the EU for commercial cultivation throughout the European bloc. According ... -
Locust Disaster in Tanzania Prevented
3 Jul 2009 | 2:00 amLocusts know no border. And for farmers in Africa, this fact can translate into disaster. A locust can consume more than its weight in food in just a day. If not controlled, large swarms of locusts will fly over vast areas of farmland, traveling over a distance of 20-30 kilometers per day and feeding on cereals, sugar cane, citrus and fruit trees, ... -
Arabic Book on Biotechnology in Egypt
3 Jul 2009 | 2:00 amA new book in Arabic on important papers for decision makers on biotechnology in Egypt has just been published by the Egypt Biotechnology Information Center (EBIC). It includes key definitions of agricultural biotechnology and provides answers to questions on the safety of biotech crops. Likewise, it highlights the role of biotech crops in the deve... -
Scientists Develop Rust-Proof Soybean for Africa
3 Jul 2009 | 2:00 amGood news for soybean farmers in West and Central Africa. The Nigeria-based International Institute for Tropical Agriculture (IITA) has developed a new variety resistant to the deadly Asian soybean rust, a disease that could wipe out as much as 80% of infested crops. Caused by the fungus Phakopsora pachyrhizi, the plant disease has wreaked havoc in... -
German Researchers Working to Develop Virus-Resistant Grapevines
3 Jul 2009 | 2:00 amThe Grapevine fanleaf virus (GFLV) is a big problem for grapevine growers. The virus causes the dreaded fanleaf disease characterized by deformed and yellowed leaves and smaller grapes, resulting to yield loss and in extreme cases, crop loss. Researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in Aachen, Germany ar...
-
Yahoo! News: Biotechnology News
-
GMO corn: France rejects report by EU food agency (AFP)
3 Jul 2009 | 10:48 amAFP - France on Friday rejected a report by the European Union's food safety watchdog that said a controversial strain of genetically-modified corn was safe. -
Tamiflu-resistant swine flu patient found in Japan: govt (AFP)
2 Jul 2009 | 2:19 pmAFP - A genetic mutation of swine flu that is resistant to the anti-viral Tamiflu has been discovered in Japan, the first such case in the country, the health ministry said. -
Study: New flu inefficient in attacking people (AP)
2 Jul 2009 | 2:03 pmAP - With swine flu continuing to spread around the world, researchers say they have found the reason it is so far more a series of local blazes than a wide-raging wildfire. The new virus, H1N1, has a protein on its surface that is not very efficient at binding with receptors in people's respiratory tracts, researchers at the Harvard-MIT Division of Health Sciences and Technology report in Friday's edition of the journal Science. -
Master Stem Cell for Human Heart Identified (HealthDay)
1 Jul 2009 | 8:49 pmHealthDay - WEDNESDAY, July 1 (HealthDay News) -- For the first time, researchers have identified a single "master" stem cell in humans that is capable of differentiating into all three major cell types that make up the human heart. -
Ill. cancer researcher wins $500K genetics prize (AP)
1 Jul 2009 | 7:17 amAP - An 84-year-old University of Chicago researcher has won a half-million-dollar genetics prize for her pioneering work in showing that cancer is a genetic disease.
-
Biology News Net - Biotechnology
-
Integrated optical trap holds particles for on-chip analysis
2 Jul 2009 | 3:17 pmA new type of optical particle trap can be used to manipulate bacteria, viruses and other particles on a chip as part of an integrated optofluidic platform. The optical trap is the latest innovation from researchers at the Jack Baskin School of Engineering at the University of California, Santa Cruz, who are developing new sensor technology for biomedical analysis and other applications. -
The sound of light: Innovative technology shatters the barriers of modern light microscopy
30 Jun 2009 | 2:15 pmIn the past, even modern technologies have failed to produce high-resolution fluorescence images from this depth because of the strong scattering of light. In the Nature Photonics journal, the Munich researchers describe how they can reveal genetic expression within live fly larvae and fish by "listening to light". In the future this technology may facilitate the examination of tumors or coronary vessels in humans. -
Making nanoparticles in artificial cells
26 Jun 2009 | 5:44 pmTwo new construction manuals are now available for the world's smallest lamps. Based on these protocols, scientists from the Max Planck Institute of Colloids and Interfaces have tailor-made nanoparticles that can be used as position lights on cell proteins and, possibly in the future as well, as light sources for display screens or for optical information technology. The researchers produced cadmium sulphide particles in microscopically small membrane bubbles. Depending on which of the construction manuals they follow, the particles can be 4 or 50 nanometres in size. Because the membrane… -
Novel handheld device detects anthrax with outstanding accuracy and reliability
25 Jun 2009 | 7:35 pmVeritide Ltd., a developer of innovative biological identification and detection solutions, today reported that new independent data to be presented at the Biodetection Technologies 2009 conference confirm the exceptional accuracy of its Ceeker™ (pronounced "seeker") portable bacterial detection device in discriminating between anthrax spores and similar-looking hoax substances. The data show that in over two weeks of testing at the Midwest Research Institute in Florida, the company's Ceeker scanner accurately identified 100% of the anthrax samples used and was correct in 95% of tests… -
A Canada-wide technology platform for mapping the human interactome
23 Jun 2009 | 3:58 pmOn June 18, the Canada Foundation for Innovation (CFI) announced the award of $9.16 million for the creation of a national technology platform aimed at mapping the human interactome. This national platform, headed by Dr. Benoit Coulombe from the Institut de recherches cliniques de Montréal (IRCM), will not only provide Canadian researchers with new state-of-the-art equipment in proteomics, functional genomics and bioinformatics, but also bring together integrated infrastructure for deciphering the human interactome an expertise that, until now, has been spread in 12 universities across…
-
Biotech News
-
Monthly pet pill could kill fleas, ticks
4 Jul 2009 | 4:37 amControlling ticks and fleas is drudgery for countless pet owners. Now, researchers report they're closer to developing a monthly pill that would conveniently rid cats and dogs of these disease-carrying invaders. -
FDA Approves Multaq for Patients with Atrial Fibrillation or Atrial Flutter
4 Jul 2009 | 12:29 amPatients with atrial fibrillation or atrial flutter soon will have a new treatment option to help improve current management of their disease. -
Latest North Dakota news, sports, business and entertainment:...
3 Jul 2009 | 8:17 pmLatest North Dakota news, sports, business and entertainment: AVENTIS SETTLEMENT ND reaches settlement with Aventis Bismarck , N.D. North Dakota is getting about $108,000 as part of a larger $95.5 million settlement with Aventis Pharmaceutical Inc. -
Sepracor tumbles as drugs suffer setback
3 Jul 2009 | 4:16 pmSepracor Inc. , a Marlborough, Mass., biotechnology company, yesterday suffered a double setback as its experimental depression drug failed a midstage study and US regulators halted two pediatric studies of its blockbuster Lunesta insomnia pill, sending shares down over 15 percent in after-hours trading. -
CombinatoRx agrees to merger with Canadian firm
3 Jul 2009 | 11:58 amA Neuromed employee at work in a company lab. The deal is expected create a stronger pipeline of drugs for CombinatoRx.
-
Journal of Agricultural and Food Chemistry: Latest Articles (ACS Publications)
-
Interaction of Copper and Human Salivary Proteins
2 Jul 2009 | 9:16 amJournal of Agricultural and Food Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). -
Determination of Stereoselective Interaction between Enantiomers of Chiral γ-Aryl-1H-1,2,4-triazole Derivatives and Penicillium digitatum
2 Jul 2009 | 9:16 amJournal of Agricultural and Food Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). -
Protectivity of Blue Honeysuckle Extract against Oxidative Human Endothelial Cells and Rat Hepatocyte Damage
2 Jul 2009 | 9:16 amJournal of Agricultural and Food Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). -
Angiotensin I Converting Enzyme Inhibitory Peptides Produced by Autolysis Reactions from Wheat Bran
2 Jul 2009 | 9:15 amJournal of Agricultural and Food Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). -
Panax notoginseng Reduces Atherosclerotic Lesions in ApoE-Deficient Mice and Inhibits TNF-α-Induced Endothelial Adhesion Molecule Expression and Monocyte Adhesion
2 Jul 2009 | 9:15 amJournal of Agricultural and Food Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable).
-
BMC Biotechnology - Latest Articles
-
Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies
29 Jun 2009 | 5:00 pmBackground: In protein engineering, site-directed mutagenesis methods are used to generate DNA sequences with mutated codons, insertions or deletions. In a widely used method, mutations are generated by PCR using a pair of oligonucleotide primers designed with mismatching nucleotides at the center of the primers. In this method, primer-primer annealing may prevent cloning of mutant cDNAs. To circumvent this problem we developed an alternative procedure that does not use forward-reverse primer pair in the same reaction. Results: In initial studies we used a double-primer PCR mutagenesis… -
Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity
29 Jun 2009 | 5:00 pmBackground: Ricin is a lethal toxin that inhibits protein synthesis. It is easily extracted from a ubiquitously grown plant, Ricinus communis, and thus readily available for use as a bioweapon (BW). Anti-ricin antibodies provide the only known therapeutic against ricin intoxication. Results: In this study, after immunizing a non-human primate (Macaca fascicularis) with the ricin chain A (RCA), a phage-displayed immune library was built (2x10E8 clones), that included the lambda light chain fragment. The library was screened against ricin, and specific binders were sequenced and further… -
Novel sequential ChIP and simplified basic ChIP protocols for promoter co-occupancy and target gene identification in human embryonic stem cells
28 Jun 2009 | 5:00 pmBackground: The investigation of molecular mechanisms underlying transcriptional regulation, particularly in embryonic stem cells, has received increasing attention and involves the systematic identification of target genes and the analysis of promoter co-occupancy. High-throughput approaches based on chromatin immunoprecipitation (ChIP) have been widely used for this purpose. However, these approaches remain time-consuming, expensive, labor-intensive, involve multiple steps, and require complex statistical analysis. Advances in this field will greatly benefit from the development and use of… -
Cell-free protein synthesis energized by slowly-metabolized maltodextrin
27 Jun 2009 | 5:00 pmBackground: Cell-free protein synthesis (CFPS) is a rapid and high throughput technology for obtaining proteins from their genes. The primary energy source ATP is regenerated from the secondary energy source through substrate phosphorylation in CFPS. Results: Distinct from common secondary energy sources (e.g., phosphoenolpyruvate - PEP, glucose-6-phosphate), maltodextrin was used for energizing CFPS through substrate phosphorylation and the glycolytic pathway because (i) maltodextrin can be slowly catabolized by maltodextrin phosphorylase for continuous ATP regeneration, (ii) maltodextrin… -
Expression of endo-1, 4-beta-xylanase from Trichoderma reesei in Pichia pastoris and functional characterization of the produced enzyme
15 Jun 2009 | 5:00 pmBackground: In recent years, xylanases have attracted considerable research interest because of their potential in various industrial applications. The yeast Pichia pastoris can neither utilize nor degrade xylan, but it possesses many attributes that render it an attractive host for the expression and production of industrial enzymes. Results: The Xyn2 gene, which encodes the main Trichoderma reesei Rut C-30 endo-β-1, 4-xylanase was cloned into the pPICZαA vector and expressed in Pichia pastoris. The selected P. pastoris strains produced as 4,350 nkat/ml β-xylanase under the control of the…
-
Biotechnology Journal
-
Molecular facets of sphingolipids: Mediators of diseases
3 Jul 2009 | 12:44 amSphingolipids constitute a biologically active lipid class that is significantly important from both structural and regulatory aspects. The manipulation of sphingolipid metabolism is currently being studied as a novel strategy for cancer therapy. The basics of this therapeutic approach lie in the regulation property of sphingolipids on cellular processes, which are important in a cell's fate, such as cell proliferation, apoptosis, cell cycle arrest, senescence, and inflammation. Furthermore, the mutations in the enzymes catalyzing some specific reactions in the sphingolipid metabolism cause… -
A simple and robust algorithm for microarray data clustering based on gene population-variance ratio metric
3 Jul 2009 | 12:44 amWith the advent of the microarray technology, the field of life science has been greatly revolutionized, since this technique allows the simultaneous monitoring of the expression levels of thousands of genes in a particular organism. However, the statistical analysis of expression data has its own challenges, primarily because of the huge amount of data that is to be dealt with, and also because of the presence of noise, which is almost an inherent characteristic of microarray data. Clustering is one tool used to mine meaningful patterns from microarray data. In this paper, we present a novel… -
Changing from computing grid to knowledge grid in life-science grid
3 Jul 2009 | 12:44 amno abstract -
Lysozyme-lysozyme self-interactions as assessed by the osmotic second virial coefficient: Impact for physical protein stabilization
3 Jul 2009 | 12:44 amThe purpose of the presented study is to understand the physicochemical properties of proteins in aqueous solutions in order to identify solution conditions with reduced attractive protein-protein interactions, to avoid the formation of protein aggregates and to increase protein solubility. This is assessed by measuring the osmotic second virial coefficient (B22), a parameter of solution non-ideality, which is obtained using self-interaction chromatography. The model protein is lysozyme. The influence of various solution conditions on B22 was investigated: protonation degree, ionic strength,… -
Application of a PEG/salt aqueous two-phase partition system for the recovery of monoclonal antibodies from unclarified transgenic tobacco extract
25 Jun 2009 | 1:49 amAqueous two-phase partition systems (ATPS) have been widely used for the separation of a large variety of biomolecules. In the present report, the application of a polyethylene glycol/phosphate (PEG/phosphate) ATPS for the separation of anti-HIV monoclonal antibodies 2G12 (mAb 2G12) and 4E10 (mAb 4E10) from unclarified transgenic tobacco crude extract was investigated. Optimal conditions that favor opposite phase partitioning of plant debris/mAb as well as high recovery and purification were found to be 13.1% w/w (PEG 1500), 12.5% w/w (phosphate) at pH 5 with a phase ratio of 1.3 and 8.25%…
-
Biotechnology and Applied Biochemistry Immediate Publications
-
The effects of crosslink density and chemistry on the calcification potential of diamine-extended glutaraldehyde-fixed bioprosthetic heart-valve materials
30 Jun 2009 | 9:18 amDespite indications that glutaraldehyde (GA) crosslinked tissues remain prone to long-term degradation and calcification, it is still the reagent of choice in the fixation of bioprosthetic heart valves. We have previously shown that increased GA concentrations and diamine extension of crosslinks with lysine incorporation lead to a mitigated in vivo calcification, mainly of porcine aortic wall tissue. The current study was performed to assess the correlation between the crosslink-density of all three commonly used tissue types (porcine aortic wall (PW), porcine aortic leaflet (PL), and bovine… -
Generation of tumor necrosis factor alpha-specific affibody molecules capable of blocking receptor binding in vitro
23 Jun 2009 | 4:08 amAffibody molecules specific for human TNFα were selected by phage-display technology from a library based on the 58-residue protein A-derived Z domain. TNFα is a proinflammatory cytokine involved in several inflammatory diseases, and to this day, four TNFα-blocking protein pharmaceuticals have been approved for clinical use. The phage selection generated 18 unique cystein-free affibody sequences of which 12 were chosen, after sequence cluster analysis, for characterization as proteins. Biosensor binding studies of the 12 E. coli-produced and IMAC-purified affibody… -
Analysis of phospholipids, sterols, and fatty acids in Taxus chinensis var. mairei cells in response to shear stress
17 Jun 2009 | 1:49 amTo obtain a better understanding of responsive mechanism of plant cells in response to hydrodynamic mechanical stress, lipid profiling of suspension cultured Taxus chinensis var. mairei cells under shear stress was carried out using LC-MS/MS and GC-TOF-MS. T. chinensis var. mairei cells cultured in Couette type shear reactor responded with an increase of cell membrane permeability compared with control cells, which indicated adaptation to shear stress altered membrane lipid composition. The main changes of lipid profiles in the shear stress induced cells were the following: a) total… -
The N-terminal modification increases the stability of the recombinant human endostatin in vitro
16 Jun 2009 | 2:01 amEndostar, approved for the treatment of non-small-cell lung cancer by the State Food and Drug Administration in China, is a derivative of human endostatin modified with an additional metal chelating sequence (MGGSHHHHH) at the N-terminus. This modification contributes to an additional zinc-binding site into endostatin sequence. In this study, zinc-binding and zinc-free endostar were compared to further characterize the biochemical and structural properties. Thermal-induced denaturation was determined by monitoring changes in the fluorescence emission spectra. The result indicated that zinc… -
Engineering and characterization of a bispecific HER2{Multiplication sign}EGFR-binding affibody molecule
3 Jun 2009 | 6:23 amThe human epidermal growth factor receptor-2 (HER2) and the epidermal growth factor receptor (EGFR) are overexpressed in various forms of cancer, and the co-expression of both HER2 and EGFR has been reported in a number of studies. The simultaneous targeting of HER2 and EGFR has been discussed as a strategy to potentially increase the efficiency and selectivity in molecular imaging and therapy of certain cancers. In an effort to generate a molecule capable of bispecific targeting of HER2 and EGFR, a gene fragment encoding a divalent HER2-binding affibody molecule was genetically fused in…
-
WordPress Tag: Biotechnology
-
Hybrid Hearts: Stem Cell Transplants 2.0
3 Jul 2009 | 10:36 pm“Can we use stem cells to make a new heart/eye/lung/liver etc?” This is the predictable and perennial question that comes up from at least one student when we are looking at stem cells, genetic engineering, cell differentiation and transplanting. Until now, the answer has (perhaps in an oversimplified way) been ‘no’. We can use stem cell transplants to treat lymphoma. Recently a young woman had a trachea transplant based on stem cell technology. Skin grafts from a patient’s own cultured cells are also possible, as are stem cell-based bladders. However, these are… -
Mass Evacuation Bus
3 Jul 2009 | 6:53 pmWhat do you all make of this? Fema’s preparation for the swine flu eugenics program? Guess t -
The Kid Is Not My....
3 Jul 2009 | 9:36 amMirror Man Diary of a Mad Law Professor by PATRICIA J. WILLIAMS This article appeared in the July 20, 2009 edition of The Nation July 1, 2009 To me, the most arresting image of Michael Jackson was President George H.W. Bush citing him as a role model for young black men. It was 1990 and Jackson was at the height of his fame. “Man in the Mirror” had been released two years earlier. Jackson had not yet gone into full white-face disguise, but the handsome little brown boy of his first album had long since entered the bizarro phase of rhinestone gloves. I wondered then what on earth… -
El coste de sacar un fármaco al mercado supera los mil millones de dólares
2 Jul 2009 | 11:47 pmPer Lindberg participó en una sesión del Máster Universitario en I+D+I de Medicamentos. Foto: Manuel Castells “El coste de llevar un producto desde su ideación hasta el mercado supera hoy los mil millones de dólares”, afirmó Per Lindberg, consejero científico senior de la multinacional farmacéutica AstraZéneca. Este experto, uno de los creadores del omeprazol, participó en el Máster Universitario en I+D+I de Medicamentos de la Universidad de Navarra. Según el investigador, alrededor del 20% de la inversión para elaborar un fármaco corresponde a la fase preclínica -aquella… -
Cuba and Portugal to Boost Cooperation
2 Jul 2009 | 11:39 pmIstock Analyst: Cuban and Portuguese government have decided to upgrade their cooperation, with special emphasis in biotecnology, the pharmaceutical industry and renewable energies. Portugal and Cuba signed here on Tuesday a declaration of strengthening cooperation in a bid to enhance relations between the two countries. Portuguese Secretary of State for Foreign Affairs and International Cooperation Joao Gomes Cravinho signed the declaration with Cuban Deputy Foreign Minister Dagoberto Rodriguez. Cravinho, who has been in Cuba on a visit since Monday, said the two countries have great…
-
Arizona Biotech News
-
Rocky Mountain Life Science Investor Conference 2009
13 Jun 2009 | 2:37 pmThe Rocky Mountain Life Science Investor Conference 2009 - Apply Now!See the the future of bioscience and your role in shaping it! On September 17th in Denver, Colorado, The Rocky Mountain Life Science Investor Conference 2009, co-hosted by AZBio and the Colorado BioScience Association, will bring together leading investors, emerging companies and senior executives of established companies from around the country. Arizona companies are encouraged to participate and apply to present Presenting companies will have a 20 minute podium presentation (including Q&A) for you to introduce your… -
BIO hosts events at UNFCCC in Bonn
11 Jun 2009 | 11:37 amBIO to Host Side Event at Bonn Climate Change Talks “Biotechnology: Solutions for Climate Change”WHAT: The Biotechnology Industry Organization (BIO) will host a side event at the upcoming UNFCCC Climate Change Talks in Bonn. Biotechnology offers a broad range of tools to address climate change. This briefing will focus on clean, renewable alternatives to petroleum-based fuels and products, reduction of greenhouse gas emissions from industrial processes, and the use of sustainable agricultural practices.WHO: Stephanie Batchelor, Manager, Industrial & Environmental Section, BIO;Willy De… -
Celera cuts its last tie to Maryland biotech
11 Jun 2009 | 10:53 amIt’s official, the end of an era. Celera Corp., once among the biggest biotech brand names in the Washington area, is shuttering its last remaining operation in the region.The company, which moved its home base to Alameda, Calif., last year, is laying off 20 of its 25 local employees and closing its 41,000-square-foot operation in Rockville by the end of the third quarter.A small number of employees working on lung cancer diagnostic tests could move to the West Coast, while only one or two employees might stay in Rockville.In its heyday, Celera employed 550 people in the company’s… -
$18 million awarded to TGen and University of Pennsylvania
28 May 2009 | 11:18 am$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research from Stand Up to CancerScottsdale Healthcare at Shea Medical Center a primary clinical sitePHOENIX, Ariz. - The Translational Genomics Research Institute (TGen) and the University of Pennsylvania (Penn) will receive $18 million to research pancreatic cancer, Stand Up to Cancer (SU2C) announced today. Dr. Daniel Von Hoff, TGen’s Physician-In-Chief, and Dr. Craig B. Thompson, Director of the Abramson Cancer Center at Penn, are co-leaders of SU2C pancreatic cancer "Dream Team," which will lead a… -
TGen intern named one of the nation’s Top 40 studentscoparomi
11 May 2009 | 2:03 pmTGen intern named one of the nation’s Top 40 students Source: TGEN ASU student also awarded $2,500 scholarship for work at TGen 05-08-2009javascript:void(0)PHOENIX, Ariz. - May 8, 2009 - Eric Anderson, who has worked for three years as an intern for the Translational Genomics Research Institute (TGen), has been named one of the nation’s Top 40 students by USA Today. Anderson, a senior at Arizona State University, was named to the national newspaper’s prestigious annual All-USA College Academic Second Team of 20 students. The First Team of 20 students also included an ASU student. (Click…
-
WordPress Tag: Bio-technology
-
Robotic Surgery
22 Jun 2009 | 5:32 amABSTRACT The field of surgery is entering a time of great change, spurred on by remarkable recent advances in surgical and computer technology. Only recently have robotic systems made their way into the operating room as dexterity-enhancing surgical assistants and surgical planners, in answer to surgeons’ demands for ways to overcome the surgical limitations of minimally invasive laparoscopic surgery. The first generation of surgical robots is already being installed in a number of operating rooms around the world. These aren’t true autonomous robots, but they are lending a… -
Brain Gate : beginning of a second, larger clinical trial
13 Jun 2009 | 5:48 amBrain-computer interface, developed at Brown, begins new clinical trial Article from biologynews.net Picture added by Atomic News Reviews The BrainGate2 pilot clinical trial is taking place at Massachusetts General Hospital (MGH), in close collaboration with an interdisciplinary team of researchers from MGH and Brown University. The study has been approved by the MGH Institutional Review Board to begin recruiting participants. The trial extends prior safety and feasibility research of the BrainGate Neural Interface System, which consists of an implanted baby aspirin-size brain sensor that… -
Twitter silenced by Chinese
4 Jun 2009 | 8:59 pmBeijing, the capital, is virtualy lockdown ! Key foreign news Web sites were blocked, dissidents were placed under house arrest, and police blanketed the vast square where a still-undetermined number of pro-democracy activists were killed in a violent clash with the military June 4, 1989. Of course , journalists were kept away from the scene. Take a look at this news from thestar.comwritten by Bill Schiller… -
Chemtrails , Carbon Tax, and Sickness!
22 May 2009 | 4:16 pmDaniel 12:4 Many will ROVE about, and the true knowledge shall become abundant. 10 and no wicked ones at all will understand! To begin with……..The following document, dated May 1979, was found on July 7, 1986, in an IBM copier that had been purchased at a surplus sale. A copy found in 1969 was in the possession of Navel Intelligence. Table of Contents TOP SECRET Silent Weapons for Quiet Wars Welcome Aboard This publication marks the 25th anniversary of the Third World War, called the “Quiet War”, being conducted using SUBJECTIVE BIOLOGICAL WARFARE , fought with… -
Canadian scientist arrested for smuggling vials for Ebola researchs
14 May 2009 | 11:13 amKonan Michel Yao is faces U.S. criminal charges for smuggling 22 viles used in Ebola research stolen from Canada's National Microbiology Lab. The viles were stolen in January, but Canada's public health agency didn't know the vials were missing until the Canadian scientist was stopped at the U.S. border last week.Photograph by: Karoly Arvai, Reuters OTTAWA — A Canadian scientist was stopped at the U.S. border last week after authorities found 22 vials used in Ebola research from Canada’s National Microbiology Lab in his possession, officials said Wednesday. The incident…
-
Bio Job Blog
-
Is Roche Really Becoming a Biotechnology Company?
30 Jun 2009 | 10:30 amWord on the street suggests that Roche has severed its relationship with the Pharmaceutical Manufacturers of America (PhRMA) the trade group that represents and lobbies on behalf of the pharmaceutical industry. The recent purchase of Genentech must have convinced the venerable 100 year old pharmaceutical company that proteins not small molecule drugs are the key to its future. According to published reports, the Biotechnology Industry Organization (BIO) has already sent an emissary to Roche's headquarters in Basel to talk to Severin Schwan, its CEO, about the benefits of BIO membership. Will… -
Greetings from Stockholm Sweden
30 Jun 2009 | 1:30 amI haven't been posting much lately because I am in Stockholm at a computational biology meeting where I am reviewing resumes and offering career guidance to PhD students and postdoctoral fellows. For those of you who have never considered visiting Stockholm, I highly recommend that you do. It is a stunning city located on an archipelago of 14 different islands. The Swedes are hospitable, the food is great and it starts getting dark around 11:00 pm. I will be back in the US after July 4. Until next time... Good Luck and Good Job Hunting!!!! … -
Obama Seeks Compromise on Length of Data Exclusivity for Follow-on Biologics
28 Jun 2009 | 9:03 amAs the Congressional debate over follow-on biologics slogs on, the Obama Administration has finally weighed in and backs 7 years of data exclusivity for follow-on biologics. As you may recall, innovator companies want a 12-14 year data exclusivity period whereas follow-on biologics manufacturers are seeking a 5-year period (which is identical to the data exclusivity period for small molecules generic drugs outlined in the Hatch Waxman Act). What this means—based on the Obama Administration's proposal—is that a follow-on biologic manufacturer must wait seven years from the date of… -
Social Media Manager--A New Career Option for PhD Life Scientists?
25 Jun 2009 | 8:07 amWhile life sciences companies are still reluctant to take the “social media plunge,” many other companies (with active social media programs) frequently hire employees known as social media managers who oversee and run their social networks. This is because successful social media websites require daily attention and are extremely time consuming and labor intensive. In general, employees who are hired for these jobs have strong backgrounds in social media and technology but frequently possess little expertise in the industry that they are working in. Because social media is… -
Biotech in Canada Eh!
24 Jun 2009 | 12:38 pmFor those of you interested in the Canadian biotechnology scene I want to mention a good resource that I came across recently. The Canadian BioTechnologist 2.0 Blog (http://cbt20.org) has its sights set on helping to advance the development of the Canadian Biotechnology sector and the people who study biotechnology and life sciences at the college and university level and bench scientists and technicians who work in the field across the country. Readers are invited to contribute content: posters, tools, research and presentations, articles white papers, multimedia, music…
-
Nature.com: Biotechnology News
-
Chief scientist quits California stem-cell agency
30 Jun 2009 | 10:44 amDeparture raises questions over leadership at flagship centre. -
Research parks feel the economic pinch
17 Jun 2009 | 2:00 pmOnce lauded as incubators of high-tech jobs, science parks find themselves struggling in the new financial environment. -
Californian universities caught in budget hell
8 Jun 2009 | 3:42 pmState-wide cash crisis shuts down building projects and recruitment plans. -
US ramps up swine flu protection
3 Jun 2009 | 3:37 pmNew technologies may help boost H1N1 vaccine production. -
Mouse patent sparks 'uncivil' spat
3 Jun 2009 | 2:00 pmAcademic institutes lock horns in legal action over mutant mice.
-
Colorado BioScience Association News Feed
-
Colorado Governor Signs Two Bills Designed to Accelerate State's Life-Sci Growth
23 Jun 2009 | 7:54 pmBioRegion News: June 5, 2009 -- Colorado Gov. Bill Ritter signed into law this week a pair of bills sought by state life science leaders.Both bills, however, include changes that scale down the tax breaks that were originally proposed through the measures, reflecting the state's need to balance its budget by wiping out a $1.4 billion shortfall blamed on the ongoing economic upheaval.Ritter on June 1 signed House Bill 09-1035, which expands the categories of business eligible for refunds of up to $50,000 in state sales and use taxes paid on personal property for research and development to… -
CBSA Applauds Gov. Ritter’s Signing of HBs 1035 & 1105, Ensuring Colo’s Position As a Thriving Location for Bioscience and Emerging Technology
2 Jun 2009 | 11:28 amDenver, CO -- Colorado Governor Bill Ritter has signed HB 1035 (expanding sales and use tax for medical device companies) and HB 1105 (Angel Investment Tax Credit), ensuring Colorado’s position as a thriving location for bioscience and emerging technology companies. The announcement is made by John Collar, President and CEO of the Colorado BioScience Association (CBSA), who on behalf of the association commends Colorado Governor Bill Ritter for signing and the following legislators for sponsoring these two important pieces of legislation:* HB 1035, sponsored by Representative Jim Riesberg… -
Colorado Again Confirmed as Top Bioscience State by National Rankings & Venture Capital Funding Activity
31 May 2009 | 2:09 pmDenver, CO -- "It's an exciting time to be a bioscience company in Colorado, and the state is continuing to garner the national attention it deserves for its top-notch bioscience industry," said John Collar, President and CEO of the Colorado BioScience Association (CBSA). "FierceBiotech highlighted Colorado as one of its top five biotech regions, and The Money Tree™ Report, recently released by Genome Technology, listed Colorado in its top 10 Venture Capital deals for both biotech and medical device and equipment."Colorado's success at attracting venture capital was demonstrated earlier… -
Boulder Daily Camera Includes CBSA/John Collar Perspective on GlobeImmune & Clovis Announcements
31 May 2009 | 1:56 pmJohn Collar, CBSA President & CEO, provided perspective to DC Reporter Alicia Wallace on both the recent GlobeImmune and Clovis Oncology announcements.Link to GlobeImmune signs partnership that could net $500MLink to Pharmion vets launch new oncology venture -
Colorado BioScience Association Featured for Second Time in European Life Science Journal
31 May 2009 | 1:39 pmLink to CBSA's article about the Colorado BioScience industry in the Spring 2009 edition -- look in the USA Section.
-
OnBioVC
-
Capella, Inc.: Series C $17.3M
28 Jun 2009 | 7:56 pmCapella (Ireland) a development-stage medical device company focused on stents for bifurcation vascular disease complex coronary artery disease, cloased a $17.3M Series C financing. Participants include Fountain Healthcare Partners, Mitsui & Co., Enterprise Ireland, Polytechnos Partners and ACT Venture Capital. -
Solazyme, Inc.: Series C $57M
28 Jun 2009 | 7:54 pmSolazyme (San Francisco, CA) a development-stage biofuels company focused on the bioproduction of microalgae molecules for the energy, chemical, and nutraceutical industries, closed a $57M Series C financing. Participants include Braemar Energy Ventures, Lightspeed Venture Partners, VantagePoint Venture Partners, Roda Group and Harris & Harris Group. -
NanoString Technologies, Inc.: Series C $30M
28 Jun 2009 | 7:51 pmNanoString Technologies (Seattle, WA) a commercial-stage developer of instrumentation and assays for multiplexed detection and quantification of gene expression, closed a $30M Series C financing. Participants include Clarus Ventures, OVP Venture Partners and Draper Fisher Jurvetson. -
Inspire Medical Systems, Inc.: Series B $17M
28 Jun 2009 | 7:49 pmInspire Medical Systems (Minneapolis, MN) an early-stage medical device company developing an implantable therapeutic device for the treatment of obstructive sleep apnea, closed a $17M Series B financing. Participants include Kleiner Perkins Caufield & Byers, Medtronic and U.S. Venture Partners. -
Spiracur, Inc.: Series B $20.3M
28 Jun 2009 | 7:47 pmSpiracur (Redwood City, CA) and early-stage medical device company focused on wound healing, closed a $20.3M Series B financing. Participants include Kleiner Perkins Caufield & Byers, New Leaf Venture Partners and De Novo Ventures.
-
BioSpace.com
-
NeoGenomics Laboratories Expansion to Create 75 New Jobs in Lee County
2 Jul 2009 | 5:00 amvar addthis_pub"bdwyer"; -
What to Discuss During Interviews for Jobs in the Biotechnology Field
2 Jul 2009 | 5:00 amvar addthis_pub"bdwyer"; -
Over 250 New Jobs at Eisai Company, Ltd.'s New HQ
2 Jul 2009 | 5:00 amvar addthis_pub"bdwyer"; -
How Does the Faltering Economy Affect Jobs in Pharmaceutical Services?
2 Jul 2009 | 5:00 amvar addthis_pub"bdwyer"; -
Johnson & Johnson to Buy $1 Billion Elan Corporation PLC Stake, Work on Alzheimer's
2 Jul 2009 | 5:00 amBloomberg -- Johnson & Johnson agreed to pay $1 billion for a stake in Elan Corp. and will develop the Irish drugmakers medicines against Alzheimers disease.
-
TradePub: Biotechnology
-
sp2
1 Jul 2009 | 9:20 amPublished monthly, coverage includes technological advances that drive research and innovation, as well as product development through key topics including: discovery biology/chemistry, biomanufacturing, bioprocessing and fine chemistry. The sp2 audience is senior R&D executives to bench scientists from pharma, biotech and emerging pharma.Request Free! -
Lab Manager Magazine
1 Jul 2009 | 12:20 amMost lab managers, by education and experience, are thoroughly capable of handling the technical aspects of their jobs, but their managerial skills are often obtained haphazardly. Lab Manager Magazine® is written with those managers in mind and has the distinct editorial mission of providing practical information on business, strategy, leadership and staffing as well as the industry and technology news needed to effectively manage today's lab.Request Free! -
American Biotechnology Laboratory
1 Jul 2009 | 12:20 amAmerican Biotechnology Laboratory will help keep you abreast of the latest developments in life science instrumentation and apparatus, bioanalytical chemistry, kits, and biologicals.Request Free! -
Nutritional Outlook
1 Jul 2009 | 12:20 amPublished nine times per year, each issue analyzes developments in regulations, ingredients, quality control, manufacturing technology, packaging, marketing and new products.Request Free! -
Pharmaceutical Executive
1 Jul 2009 | 12:20 amWhen pharmaceutical decision makers need news and insights about pharma's future and how to respond to it, they turn to Pharmaceutical Executive magazine. From strategy to marketing to the best new ideas about sales, R&D, regulations, finance, meetings and IT, Pharmaceutical Executive covers it all.Request Free!
-
Bioresearch Online News
-
R&D Logic's Unique Products And Services Offering Gaining Momentum With Leading Life Sciences Companies
2 Jul 2009 | 3:38 amR&D Logic, preferred provider of web based business management software specific to the Life Sciences Industry, today announced five new additions to their Life Sciences Customer Community. -
Intravenous COTI-2 In Combination With Doxil (Doxorubicin HCl) Is More Effective Than Treatment With Doxil Alone In An Animal Model Of Human Ovarian Cancer
2 Jul 2009 | 3:22 amCritical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility. -
Stemedica Discovers Significant Breakthrough In The Use Of Stem Cells And Stem Cell Factors For The Treatment Of Retinal Degeneration
1 Jul 2009 | 2:52 amStemedica Cell Technologies, Inc., ("Stemedica"),a leader in the manufacturing and development of clinical grade allogeneic adult stem cell technology, has discovered a significant breakthrough in the use of human stem cells and stem cell factors for the potential treatment of degenerations of the retina and retinal pigmented epithelium. -
New NIMBUS System Automates Vacuum-Based SPE
1 Jul 2009 | 2:04 amHamilton Robotics introduces MICROLAB® NIMBUS NVS (NIMBUS Vacuum System), an integrated platform for automated vacuum-based separations. NIMBUS NVS integrates liquid handling workstation capabilities with a vacuum manifold, pump and collection device for solid-phase extraction (SPE) of analytes from complex biological mixtures in 96-well plate format. -
Morphotek, Inc. Announces A Research Collaboration Agreement With Synageva BioPharma Corporation To Develop Potential Treatments For Cancer And Infectious Disease
30 Jun 2009 | 10:12 pmMorphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.
